This review discusses non-genotoxic conditioning approaches in hematopoietic stem cell therapies, highlighting their potential to improve safety and effectiveness.
Key Points
Next-generation non-genotoxic conditioning enhances safety in hematopoietic stem cell transplants, reducing infections and toxicities.
Compared to traditional regimens, these new methods selectively target HSCs while sparing other crucial cells, promoting better outcomes.
Emerging agents such as immunotoxins and monoclonal antibodies show promise in targeted HSC elimination, based on recent clinical breakthroughs.
These innovations could significantly expand patient access to hematopoietic stem cell therapies, indicating a shift in treatment paradigms.